The entire industry agrees on where AI belongs first in a launch. Pfizer already built it, and named it after the man who founded the company. The short version: • Pfizer's Charlie is the clearest real-world proof of the MLR consensus, and it works because it routes risk to humans faster rather than deciding anything itself. • It's the lowest-regret AI win in launch, and worth building. • But the pitch assumes the review was the bottleneck, and the real delay usually sits ups